Compounds > ranolazine
Page last updated: 2024-08-24

ranolazine and Hypertension

ranolazine has been researched along with Hypertension in 7 studies

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's6 (85.71)24.3611
2020's1 (14.29)2.80

Authors

AuthorsStudies
Arndt, TL; Bennett, NM; Garberich, RF; Henry, TD; Schmidt, CW; Storey, KM; Traverse, JH; Wang, J1
Alsina, KM; Chen, C; Duan, Q; He, M; Li, X; Ni, L; Nie, J; Wang, B; Wang, DW; Wehrens, XHT; Wen, Z; Wu, L; Zhou, C1
Aistrup, GL; Belardinelli, L; Beussink, L; Chirayil, N; El-Bizri, N; Gupta, DK; Kelly, JE; Misener, S; Mongkolrattanothai, T; Nahhas, A; Ng, J; O'Toole, MJ; Rajamani, S; Reddy, M; Shah, SJ; Shryock, JC; Singh, N; Wasserstrom, JA1
Fedida, D; Lin, S; McAfee, D; Pourrier, M; Williams, S1
Berrino, L; Cappetta, D; Ciuffreda, LP; De Angelis, A; Donniacuo, M; Esposito, G; Ferraiolo, FA; Piegari, E; Rinaldi, B; Rivellino, A; Rossi, F; Russo, R; Urbanek, K1
Baker, SP; Belardinelli, L; Hintze, TH; Messina, E; Ochoa, M; Shryock, JC; Walsh, E; Wu, Y; Xu, X; Zeng, D; Zhao, G1
Aiba, T; Begley, MJ; Boström, P; Cantley, LC; Das, S; del Monte, F; Ellinor, PT; Graham, EL; Hessler, K; Knight, AC; Morissette, MR; Ottaviano, FG; Quintero, PA; Rosenberg, M; Rosenzweig, A; Tomaselli, GF; Xiao, C1

Other Studies

7 other study(ies) available for ranolazine and Hypertension

ArticleYear
Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Ranolazine Refractory Registry).
    The American journal of cardiology, 2020, 08-15, Volume: 129

    Topics: Aged; Angina Pectoris; Cardiovascular Agents; Constipation; Deprescriptions; Diabetes Mellitus; Disease Progression; Dizziness; Drug Costs; Dyslipidemias; Edema; Female; Humans; Hypertension; Male; Medication Adherence; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Nausea; Ranolazine; Registries; Smoking; Treatment Failure; Treatment Outcome

2020
Ranolazine prevents pressure overload-induced cardiac hypertrophy and heart failure by restoring aberrant Na
    Journal of cellular physiology, 2019, Volume: 234, Issue:7

    Topics: Animals; Calcium; Cardiomegaly; Cardiovascular Agents; Cell Line; Fibrosis; Heart Failure; Hypertension; Male; Mice; Mice, Inbred C57BL; Myocytes, Cardiac; Random Allocation; Ranolazine; Sodium

2019
Inhibition of the late sodium current slows t-tubule disruption during the progression of hypertensive heart disease in the rat.
    American journal of physiology. Heart and circulatory physiology, 2013, Oct-01, Volume: 305, Issue:7

    Topics: Acetanilides; Animals; Calcium Channels, L-Type; Calcium Signaling; Disease Models, Animal; Disease Progression; Dose-Response Relationship, Drug; Heart Failure; Hypertension; Hypertrophy, Left Ventricular; Male; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Ryanodine Receptor Calcium Release Channel; Sarcoplasmic Reticulum Calcium-Transporting ATPases; Sodium; Sodium Channel Blockers; Sodium Channels; Sodium-Calcium Exchanger; Time Factors; Ultrasonography

2013
Ranolazine improves diastolic function in spontaneously hypertensive rats.
    American journal of physiology. Heart and circulatory physiology, 2014, Volume: 306, Issue:6

    Topics: Acetanilides; Aging; Animals; Blood Pressure; Calcium; Cells, Cultured; Diastole; Disease Models, Animal; Dobutamine; Enzyme Inhibitors; Hypertension; In Vitro Techniques; Male; Myocytes, Cardiac; Piperazines; Ranolazine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Tetrodotoxin; Ventricular Dysfunction, Left

2014
Long-term administration of ranolazine attenuates diastolic dysfunction and adverse myocardial remodeling in a model of heart failure with preserved ejection fraction.
    International journal of cardiology, 2016, Aug-15, Volume: 217

    Topics: Animals; Cardiovascular Agents; Disease Models, Animal; Drug Administration Schedule; Heart Failure; Humans; Hypertension; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Ranolazine; Rats; Rats, Inbred Dahl; Signal Transduction; Stroke Volume; Treatment Outcome; Ventricular Remodeling

2016
Antiadrenergic and hemodynamic effects of ranolazine in conscious dogs.
    Journal of cardiovascular pharmacology, 2011, Volume: 57, Issue:6

    Topics: Acetanilides; Adrenergic Antagonists; Animals; Autonomic Agents; Coronary Circulation; Dogs; Dose-Response Relationship, Drug; Ganglionic Blockers; Guinea Pigs; Heart Rate; Hemodynamics; Hexamethonium; Hypertension; Hypotension; Isoproterenol; Kinetics; Phenylephrine; Piperazines; Ranolazine; Rats; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Vasoconstrictor Agents; Vasodilator Agents

2011
Pathological role of serum- and glucocorticoid-regulated kinase 1 in adverse ventricular remodeling.
    Circulation, 2012, Oct-30, Volume: 126, Issue:18

    Topics: Acetanilides; Animals; Cardiomegaly, Exercise-Induced; Cardiomyopathy, Dilated; Consensus Sequence; Disease Models, Animal; Electrocardiography; Enzyme Induction; Heart Failure; Humans; Hypertension; Immediate-Early Proteins; Ion Channel Gating; Mice; Mice, Inbred C57BL; Mice, Transgenic; NAV1.5 Voltage-Gated Sodium Channel; Phosphatidylinositol 3-Kinases; Phosphorylation; Piperazines; Protein Interaction Mapping; Protein Processing, Post-Translational; Protein Serine-Threonine Kinases; Ranolazine; Sodium Channel Blockers; Tachycardia, Ventricular; Ventricular Remodeling

2012